Neurofibromatosis Type 1 Therapeutics
1. Gomekli patent expiration
Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurof...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11084780 | SPRINGWORKS | Door construction |
Feb, 2041
(15 years from now) | |
| US11066358 | SPRINGWORKS | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12295925 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(15 years from now) | |
| US11883375 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US12324791 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US11839595 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US11819487 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(15 years from now) | |
| US11806322 | SPRINGWORKS | Mirdametinib treatment |
Apr, 2043
(17 years from now) | |
| US11806321 | SPRINGWORKS | Non-linear dosing of mirdametinib |
Feb, 2041
(15 years from now) | |
| US11453641 | SPRINGWORKS | Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
Feb, 2041
(15 years from now) | |
| US12263146 | SPRINGWORKS | Non-linear dosing of mirdametinib |
Feb, 2041
(15 years from now) | |
| US12257215 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US12357597 | SPRINGWORKS | NA |
Feb, 2041
(15 years from now) | |
| US12275688 | SPRINGWORKS | Crystalline solids of MEK inhibitor N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(15 years from now) | |
| US12390430 | SPRINGWORKS | NA |
Oct, 2044
(18 years from now) | |
| US12383517 | SPRINGWORKS | NA |
Mar, 2044
(18 years from now) | |
| US12011424 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(15 years from now) | |
| US12220390 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(17 years from now) | |
| US12090128 | SPRINGWORKS | Dispersible formulations of n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and uses thereof |
Feb, 2041
(15 years from now) | |
| US12037306 | SPRINGWORKS | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
Feb, 2041
(15 years from now) | |
| US12029711 | SPRINGWORKS | Dosage forms of mirdametinib |
Mar, 2044
(18 years from now) | |
| US11571402 | SPRINGWORKS | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 11, 2030 |
| Orphan Drug Exclusivity(ODE-488) | Feb 11, 2032 |
Drugs and Companies using MIRDAMETINIB ingredient
NCE-1 date: 11 February, 2029
Market Authorisation Date: 11 February, 2025
Dosage: TABLET, FOR SUSPENSION; CAPSULE
More Information on Dosage
GOMEKLI family patents
2. Koselugo patent expiration
Treatment: Treatment of pediatric patients 1 year of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neuro...
KOSELUGO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9562017 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(11 months from now) | |
| US9156795 | ASTRAZENECA | Hydrogen sulfate salt |
Dec, 2026
(11 months from now) | |
| US8178693 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2026
(2 months from now) | |
| US7425637 | ASTRAZENECA | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2026
(2 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12364684 | ASTRAZENECA | NA |
Mar, 2029
(3 years from now) | |
| US11813246 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| US12318367 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| US12220403 | ASTRAZENECA | Pharmaceutical composition |
Mar, 2029
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Apr 10, 2025 |
| ODE*(ODE*) | Apr 10, 2027 |
| Orphan Drug Exclusivity(ODE-288) | Apr 10, 2027 |
| New Product(NP) | Sep 10, 2028 |
| New Patient Population(NPP) | Sep 10, 2028 |
Drugs and Companies using SELUMETINIB SULFATE ingredient
Market Authorisation Date: 10 September, 2025
Dosage: GRANULE; CAPSULE
More Information on Dosage
KOSELUGO family patents